Parabilis Medicines
Mathai Mammen, M.D., Ph.D., serves as the CEO, President, and Chairman of Parabilis Medicines since June 2023, focusing on discovering and developing impactful medicines for patients. Mammen is also a member of the Board of Directors for Kelonia Therapeutics, Xaira Therapeutics, and Sandoz, while holding an Executive Advisor position at General Atlantic and previously contributing to 10x Genomics and Johnson & Johnson. Notably, Mammen was Executive Vice President of Pharmaceuticals and R&D at Johnson & Johnson from June 2017 to February 2023, overseeing significant advancements in the company's pharmaceutical R&D. Mammen's extensive experience includes senior leadership roles at Merck, Theravance Biopharma, and Innoviva, alongside academic credentials from prestigious institutions including Harvard Medical School, Harvard University, MIT, and Dalhousie University.
This person is not in any teams
Parabilis Medicines
Parabilis Medicines™ is a clinical-stage biopharmaceutical company dedicated to creating extraordinary medicines for people living with cancer. Through our pioneering Helicon™ discovery platform, Parabilis is engineering precisely-tuned, stabilized helical peptide therapeutics that have the potential to unlock a large number of traditionally undruggable targets. FOG-001, our first-in-class TCF-blocking β-catenin inhibitor and lead clinical program, is being evaluated in a Phase 1/2 study for patients with colorectal cancer and other solid tumors and is proof of the applicability of our platform to address undruggable intracellular protein-protein targets. We are additionally advancing a pipeline of other first-in-class programs that target proteins known to be relevant to numerous cancers, but considered intractable with traditional drug modalities. The versatility of the Helicon approach allows for the discovery of multiple targeting mechanisms, including functional protein-protein interaction inhibitors, bifunctional degraders, and radioligand therapeutics. We are headquartered in Cambridge, Mass., and are well-capitalized, with more than $500 million raised to date from leading life sciences investors. For more information, please visit: www.parabilismed.com